Spots Global Cancer Trial Database for A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Official Title: An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)
Study ID: NCT06157827
Conditions
Study Description
Brief Summary: An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
Detailed Description: This trial includes two parts: phase Ib and phase II study. Phase Ib is a dose-escalation phase and Phase II is a dose-expansion phase. Phase Ib program to enroll patients with advanced neuroendocrine carcinoma (NEC) without systemic therapy. To sequentially evaluate the safety and tolerability of LBL-024 in combination with etoposide and platinum (cisplatin or carboplatin) at different doses by the dose-escalation method. Phase II program to enroll approximately 50 patients with advanced neuroendocrine carcinoma without systemic treatment. This trial will enroll 68 patients in Phase Ib and Phase II study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Hospital, Hefei, Anhui, China
Anhui Cancer Hospital, Hefei, Anhui, China
Beijing GoBroad Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Xiangyang Central Hospital, Xiangyang, Hubei, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Liaoning Cancer Hospital, Shenyang, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Shandong Cancer Hospital, Jinan, Shandong, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Shanxi Cancer hospital, Taiyuan, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: lin shen
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
